Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · IEX Real-Time Price · USD
16.64
+1.26 (8.19%)
At close: Apr 23, 2024, 4:00 PM
16.95
+0.31 (1.86%)
Pre-market: Apr 24, 2024, 7:57 AM EDT
Company Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers.
Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Day One Biopharmaceuticals, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | May 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 501 Brisbane, California 94005 United States | |
| Phone | 650 484-0899 |
| Website | dayonebio.com |
Stock Details
| Ticker Symbol | DAWN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001845337 |
| CUSIP Number | 23954D109 |
| ISIN Number | US23954D1090 |
| Employer ID | 83-2415215 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Bender M.B.A., Ph.D. | Chief Executive Officer, President and Director |
| Dr. Samuel C. Blackman M.D., Ph.D. | Co-Founder and Head of Research & Development |
| Charles N. York II, M.B.A. | Chief Operating Officer, Chief Financial Officer and Secretary |
| Adam Dubow | General Counsel and Chief Compliance Officer |
| Dr. Mike Preigh Ph.D. | Chief of Technology Operations |
| Jaa Roberson | Chief People Officer |
| Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Development Officer |
| Lauren Merendino M.B.A. | Chief Commercial Officer |
| Dr. Elly Barry M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | ARS | Filing |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 27, 2024 | 144 | Filing |
| Feb 26, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 144 | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |